›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:ACTOnco
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
PreneticsType:
Laboratory Developed Test
Related tests:
ACTOnco is a diagnostic test which provides a comprehensive genomic profiling test that looks at 440 cancer-associated genes. It provides information to help guide clinical management decisions on the use of targeted oncology therapies, including immunotherapies. It is intended as a pan-cancer test including breast, colon, endometrial, lung, and other cancers. An FDA-cleared platform for comprehensive genomic profiling assay development for biopharma companies developing precision therapeutics.
Cancer:
Breast Cancer, Colon Cancer, Endometrial Cancer, Lung Cancer
Gene:
ABL1 (ABL proto-oncogene 1), ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase), ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), CHEK1 (Checkpoint kinase 1), CHEK2 (Checkpoint kinase 2)
See More ...
ABL1 (ABL proto-oncogene 1), ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase), ALK (Anaplastic lymphoma kinase), BRAF (B-raf proto-oncogene), CHEK1 (Checkpoint kinase 1), CHEK2 (Checkpoint kinase 2), CREBBP (CREB binding protein), EGFR (Epidermal growth factor receptor), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), MET (MET proto-oncogene, receptor tyrosine kinase), NRG1 (Neuregulin 1), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
Method:
Comprehensive Genomic Profiling
